$VRPX
Virpax Pharmaceuticals, Inc.

2021 Q3 Form 10-Q Financial Statement

#000121390021059338 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.552M
YoY Change
% of Gross Profit
Research & Development $400.0K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $400.0K
YoY Change
Operating Profit -$3.250M
YoY Change
Interest Expense -$28.89K
YoY Change
% of Operating Profit
Other Income/Expense, Net $62.92K
YoY Change
Pretax Income -$3.216M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$3.216M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share -$0.53
Diluted Earnings Per Share -$534.9K
COMMON SHARES
Basic Shares Outstanding 6.012M shares
Diluted Shares Outstanding 6.012M shares

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.71M
YoY Change
Cash & Equivalents $41.71M
Short-Term Investments
Other Short-Term Assets $1.560M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.27M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $43.27M
Total Long-Term Assets $0.00
Total Assets $43.27M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.812M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.812M
Total Long-Term Liabilities
Total Liabilities $1.812M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.46M
YoY Change
Total Liabilities & Shareholders Equity $43.27M
YoY Change

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$3.216M
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.743M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 35.99M
YoY Change
NET CHANGE
Cash From Operating Activities -4.743M
Cash From Investing Activities
Cash From Financing Activities 35.99M
Net Change In Cash 31.25M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$4.743M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001708331
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2020Q2 vrpx Stock Issued During Period Value Restricted Stock Awards Granted
StockIssuedDuringPeriodValueRestrictedStockAwardsGranted
USD
vrpx Deferred Financing Costs Included In Accounts Payable And Accrued Expenses
DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
USD
vrpx Debt Issued In Payment Of Consulting Services And Settlement Of Accounts Payable
DebtIssuedInPaymentOfConsultingServicesAndSettlementOfAccountsPayable
USD
CY2020 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
USD
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
USD
CY2021Q2 vrpx Stock Issued During Period Value Restricted Stock Awards Granted
StockIssuedDuringPeriodValueRestrictedStockAwardsGranted
USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
USD
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
USD
us-gaap Other Noncash Expense
OtherNoncashExpense
USD
vrpx Forgiveness Of Ppp Loans
ForgivenessOfPPPLoans
USD
CY2021Q3 vrpx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodIntrinsicValue
USD
vrpx Common Stock Issued In Payment Of Consulting Services And Settlement Of Accounts Payables
CommonStockIssuedInPaymentOfConsultingServicesAndSettlementOfAccountsPayables
USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
USD
CY2021Q3 vrpx Total Related Party Notes Payable Debt Forgiveness
TotalRelatedPartyNotesPayableDebtForgiveness
USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
vrpx Common Stock Issued In Payment Of Consulting Services And Settlements Of Accounts Payable
CommonStockIssuedInPaymentOfConsultingServicesAndSettlementsOfAccountsPayable
USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
USD
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
USD
CY2021Q3 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
USD
CY2021Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
USD
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
USD
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
USD
vrpx Proceeds From Secondary Offering Of Common Stock
ProceedsFromSecondaryOfferingOfCommonStock
USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
USD
us-gaap Interest Paid Net
InterestPaidNet
USD
CY2021Q3 vrpx Total Related Party Notes Payable Ending Balance
TotalRelatedPartyNotesPayableEndingBalance
USD
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
USD
CY2021Q3 vrpx Total Noncurrent Portion Of Notes Payable Debt Forgiveness
TotalNoncurrentPortionOfNotesPayableDebtForgiveness
USD
CY2021Q3 vrpx Total Noncurrent Portion Of Notes Payable Issued
TotalNoncurrentPortionOfNotesPayableIssued
USD
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares

Files In Submission

Name View Source Status
0001213900-21-059338-index-headers.html Edgar Link pending
0001213900-21-059338-index.html Edgar Link pending
0001213900-21-059338.txt Edgar Link pending
0001213900-21-059338-xbrl.zip Edgar Link pending
f10q0921ex31-1_virpaxpharma.htm Edgar Link pending
f10q0921ex31-2_virpaxpharma.htm Edgar Link pending
f10q0921ex32-1_virpaxpharma.htm Edgar Link pending
f10q0921_virpaxpharma.htm Edgar Link pending
f10q0921_virpaxpharma_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vrpx-20210930.xsd Edgar Link pending
vrpx-20210930_cal.xml Edgar Link unprocessable
vrpx-20210930_def.xml Edgar Link unprocessable
vrpx-20210930_lab.xml Edgar Link unprocessable
vrpx-20210930_pre.xml Edgar Link unprocessable